Founded in 2017 by two respiratory clinicians following 11 yrs of NHS-led and funded research.

Our Mission

To improve the lives of people with COPD through life-changing digital predictive solutions that prevent 50% of COPD-related hospitalisations and re-admissions.

Our Vision

To be a global leader in personalised prediction and prevention of COPD exacerbations: making a difference to the lives of people with COPD

Our Evidence

Clinical studies demonstrated 97% reduction in hospital admissions using predict to prevent intervention as part of proactive self-management.

Our Partners

Patients, clinicians, hospitals, policy makers and Industry provide a robust eco-system to ensure our products remain cutting edge and competitive.

“COPD is third leading cause of death worldwide, exceeded only by heart disease and stroke.”

“COPD is second major cause of unplanned hospital admissions accounting for 12% of total admissions.”


NEPeSMO offers a smart CE-marked digital monitoring solution with analytics for the prediction of COPD exacerbations and prevention of hospitalisations. COPDPredicthas been co-designed with patients and is bespoke to patients living with COPD. Proprietary prediction algorithms are constructed from time-series data on symptoms, lung function and biomarkers in blood/saliva supplied by patients using a bespoke App that connects wirelessly to monitoring devices. A dedicated web-based Clinician Early Warning System provides the healthcare team with real-time information on their patients and alerts on impending exacerbations, allowing prompt intervention.

Aspects of COPDPredict™ are patent-protected: US 8,812,249 B2; Canada 2,766,699 C and EP 2446386 B1.

What Our Patients say

Direct quotes from COPD patients using our Predict to Prevent intervention.

Co-Founder & Chief Executive Officer
Neil Patel

Respiratory physician, named inventor on patents. 10 years’ experience in managing project finances/records and research background in saliva diagnostics and prediction algorithm construction.

Co-Founder & Director of Operations
Monica Spiteri

Respiratory physician with 30 yrs+ experience working in the NHS. Named inventor on patents. Held executive leadership roles in European Respiratory and British Thoracic Societies. External advisor, EC Horizon 2020 Personalising Healthcare and various pharmaceutical companies.

Latest News

FDA Approval for COPDPredict

Manchester, UK June 28, 2021 – NEPeSMO Ltd, a pioneer in driven, self-monitoring solutions for the prediction of exacerbation in patients with chronic lung diseases is pleased to announce that the Federal Food and Drug Administration (FDA) have accepted for review the de novo regulatory application for COPDPredict™ that was submitted by the Company on June 9th, 2021.

More details

Manchester, UK June 21, 2021 – NEPeSMO Ltd, a pioneer in driven, self-monitoring solutions for the prediction of exacerbation in patients with chronic lung diseases is pleased to announce that the publication of the clinical study data, that validated the exacerbation prediction algorithm within its proprietary digital health application, COPDPredict™.

International Journal of Chronic Obstructive Pulmonary Disease 2021:16; 1887-1899.

More details
Contact Us For Collaborations, Questions Or To Say Hi

For all enquires related to sales, demos, investment opportunities etc , please contact us on info@nepesmo.com

Office Address

76 King Street,

Manchester, M2 4NH,

United Kingdom,

Registered Address

TC Group, Level 1, Devonshire House,
One Mayfair Place,
London W1J 8AJ
United Kingdom